ArticlePediatric rheumatology online journal2026
Clinical characteristics and vascular involvement of Takayasu arteritis versus Kawasaki disease in infants and young children.
Article in Pediatric rheumatology online journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Refractory Kawasaki Disease in Infants Complicated with Giant Coronary Artery Aneurysms and Takayasu Arteritis: A Rare Case Report and Literature Review.Vascular health and risk management · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundChildhood-onset Takayasu arteritis (c-TAK) in infants and young children often presents with systemic inflammation rather than ischemic symptoms, and its clinical features overlap with intravenous immunoglobulin (IVIG)-resistant Kawasaki disease (KD). To aid in early differentiation, this study compared clinical characteristics and vascular involvement between c-TAK and IVIG-resistant KD in infants and young children.
methodsThis single-center retrospective cohort study included patients under three years old diagnosed with c-TAK or IVIG-resistant KD between June, 2016, and December, 2025. Demographics, clinical presentation, laboratory findings, vascular involvement, immunotherapy, and outcomes were compared between groups.
resultsA total of 144 infants and young children were enrolled, including 43 with c-TAK and 101 with IVIG-resistant KD. Compared to the IVIG-resistant KD group, the c-TAK group had a significantly higher proportion of infants (85.7% vs. 29.7%) and females (67.4% vs. 32.7%), longer fever duration (18 [9, 26] vs. 11 [9, 13] days), higher lymphocyte counts (7.09 [5.58, 9.02] vs. 2.92 [2.18, 3.91] × 10⁹/L), and more medium-to-giant coronary artery aneurysms (CAAs; 48.8% vs. 18.8%; all P < 0.001). At the baseline, 76.7% of c-TAK patients received IVIG but experienced recurrent fever. The imaging features in the c-TAK group included vessel wall thickening (95.3%), dilation (79.1%), and stenosis (41.9%). The most commonly involved arteries were the carotid (79.1%), abdominal aorta (69.8%), subclavian (67.4%), and coronary artery (67.4%). Conversely, the IVIG-resistant KD group mainly exhibited CAAs (29.7%). The median follow-up duration was comparable between the two groups (21.0 [11.8, 45.5] vs. 18.0 [12.0, 36.0] months, P = 0.952). By the final follow-up, vascular imaging abnormalities completely resolved in 10.3% of c-TAK patients and 96.9% of IVIG-resistant KD patients.
conclusionIn young children, particularly female infants, who present with prolonged fever and a poor response to IVIG, c-TAK should be considered as an important differential diagnosis alongside IVIG-resistant KD. The distribution of vascular involvement, detailed imaging characteristics and regular follow-up may be helpful for the differential diagnosis of these two diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.